Sagimet Biosciences files for IPO in heated NASH field

Two years after filing to go public and then backing out, Sagimet Biosciences has made plans to try again to IPO.

The California biotech filed its S-1 with financial regulators on Friday, the same day it released interim Phase IIb data on its potential NASH treatment, called denifanstat. In an…
Click here to view original post

Advertisement — Advertise with Biotech Networks